ECSP21015491A - Administración prolongada de lasmiditan por la noche para la prevención de la migraña - Google Patents

Administración prolongada de lasmiditan por la noche para la prevención de la migraña

Info

Publication number
ECSP21015491A
ECSP21015491A ECSENADI202115491A ECDI202115491A ECSP21015491A EC SP21015491 A ECSP21015491 A EC SP21015491A EC SENADI202115491 A ECSENADI202115491 A EC SENADI202115491A EC DI202115491 A ECDI202115491 A EC DI202115491A EC SP21015491 A ECSP21015491 A EC SP21015491A
Authority
EC
Ecuador
Prior art keywords
migraine
prevention
night
meditan
prolonged administration
Prior art date
Application number
ECSENADI202115491A
Other languages
English (en)
Inventor
Gudarz Davar
Kirk Willis Johnson
Robert Russell Conley
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP21015491A publication Critical patent/ECSP21015491A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere al uso prolongado de lasmiditan por la noche para la prevención de la migraña, particularmente la migraña resistente al tratamiento que se define en el presente documento como migraña refractaria a dos o más esquemas de prevención o tratamiento previos de monoterapia y/o terapia doble.
ECSENADI202115491A 2018-09-04 2021-03-04 Administración prolongada de lasmiditan por la noche para la prevención de la migraña ECSP21015491A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862726585P 2018-09-04 2018-09-04

Publications (1)

Publication Number Publication Date
ECSP21015491A true ECSP21015491A (es) 2021-04-29

Family

ID=68051892

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202115491A ECSP21015491A (es) 2018-09-04 2021-03-04 Administración prolongada de lasmiditan por la noche para la prevención de la migraña

Country Status (35)

Country Link
US (1) US20210338655A1 (es)
EP (2) EP4279132A3 (es)
JP (2) JP7321256B2 (es)
KR (1) KR102649644B1 (es)
CN (1) CN112638383A (es)
AU (2) AU2019336667B2 (es)
BR (1) BR112021002945A2 (es)
CA (1) CA3111205A1 (es)
CL (1) CL2021000529A1 (es)
CO (1) CO2021002766A2 (es)
CR (1) CR20210126A (es)
DK (1) DK3846810T3 (es)
DO (1) DOP2021000039A (es)
EA (1) EA202190440A1 (es)
EC (1) ECSP21015491A (es)
ES (1) ES2967665T3 (es)
FI (1) FI3846810T3 (es)
HR (1) HRP20231587T1 (es)
HU (1) HUE064519T2 (es)
IL (1) IL281208A (es)
JO (1) JOP20210033A1 (es)
LT (1) LT3846810T (es)
MA (1) MA53551B1 (es)
MD (1) MD3846810T2 (es)
MX (1) MX2021002474A (es)
NZ (1) NZ774400A (es)
PE (1) PE20211599A1 (es)
PH (1) PH12021550448A1 (es)
PL (1) PL3846810T3 (es)
PT (1) PT3846810T (es)
RS (1) RS64857B1 (es)
SG (1) SG11202101530PA (es)
SI (1) SI3846810T1 (es)
TW (1) TWI826514B (es)
WO (1) WO2020051137A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015119848A1 (en) 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
MX2023001071A (es) * 2020-07-29 2023-05-12 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
TWI263497B (en) * 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
PL2413933T5 (pl) * 2009-04-02 2021-10-18 Colucid Pharmaceuticals, Inc. 2,4,6-trifluoro-N-[6-(1-metylopiperydyno-4-karbonylo)pirydyn-2-ylo]benzamid do leczenia migreny drogą doustną lub dożylną
CA2795062A1 (en) * 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists

Also Published As

Publication number Publication date
AU2019336667A1 (en) 2021-03-11
DK3846810T3 (da) 2023-12-04
JP2023156344A (ja) 2023-10-24
TWI826514B (zh) 2023-12-21
LT3846810T (lt) 2024-01-10
JOP20210033A1 (ar) 2021-02-25
EP4279132A2 (en) 2023-11-22
NZ774400A (en) 2024-03-22
MD3846810T2 (ro) 2024-04-30
CN112638383A (zh) 2021-04-09
PH12021550448A1 (en) 2021-09-27
EA202190440A1 (ru) 2021-06-24
AU2022291568A1 (en) 2023-02-02
FI3846810T3 (fi) 2023-12-15
DOP2021000039A (es) 2021-03-31
EP3846810B1 (en) 2023-10-18
MA53551B1 (fr) 2023-11-30
PE20211599A1 (es) 2021-08-18
ES2967665T3 (es) 2024-05-03
TW202033197A (zh) 2020-09-16
CA3111205A1 (en) 2020-03-12
EP3846810A1 (en) 2021-07-14
KR20210039419A (ko) 2021-04-09
WO2020051137A1 (en) 2020-03-12
PT3846810T (pt) 2023-12-14
CO2021002766A2 (es) 2021-03-19
CL2021000529A1 (es) 2021-08-13
RS64857B1 (sr) 2023-12-29
US20210338655A1 (en) 2021-11-04
MX2021002474A (es) 2021-08-24
KR102649644B1 (ko) 2024-03-21
EP4279132A3 (en) 2024-03-06
AU2019336667B2 (en) 2022-09-29
SG11202101530PA (en) 2021-03-30
PL3846810T3 (pl) 2024-03-18
IL281208A (en) 2021-04-29
HUE064519T2 (hu) 2024-03-28
JP7321256B2 (ja) 2023-08-04
BR112021002945A2 (pt) 2021-05-11
MA53551A (fr) 2022-01-12
JP2021535913A (ja) 2021-12-23
CR20210126A (es) 2021-04-22
HRP20231587T1 (hr) 2024-03-15
SI3846810T1 (sl) 2023-12-29

Similar Documents

Publication Publication Date Title
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
CL2019001292A1 (es) Nuevos derivados de quinolina.
ECSP21015491A (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
CL2020000301A1 (es) Nuevos derivados de quinolina.
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
DOP2017000268A (es) Metodos y kits para tratar depresion
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CR20180495A (es) Deribados de indol sustituidos como inhibidores de replicación viral del dengue
BR112017006299A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
CR20190447A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
CL2019003078A1 (es) Nuevos derivados de pirazol bicíclicos.
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
EA201791696A1 (ru) Композиция для лечения веноокклюзионной болезни печени
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CL2016001977A1 (es) Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias.
MX2020003554A (es) Moduladores de la expresion de enac.
CL2015001705A1 (es) Uso de pidotimod para tratar la psoriasis